mitoxantrone has been researched along with Mesothelioma in 9 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a multicenter phase II trial to evaluate the impact on the activity, efficacy, symptom control and safety of using two active regimens in a sequential schedule (cisplatin/gemcitabine followed by mitoxantrone/methotrexate/mitomycin) as first-line chemotherapy for unresectable malignant pleural mesothelioma (MPM)." | 9.12 | Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). ( Benedetti, G; De Pangher Manzini, V; Del Conte, G; dell'Amore, D; Galetta, D; Giaquinta, S; Lopez, M; Marino, A; Martoni, A; Mazzanti, P; Piana, E; Pinto, C, 2006) |
| "A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment." | 7.68 | Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992) |
| "46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks." | 7.68 | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. ( Dalesio, O; Giaccone, G; Kirkpatrick, A; Mattson, K; Planteydt, HT; van Breukelen, FJ; van Zandwijk, N, 1991) |
| " The aim of this study was to assess the response of four mesothelioma cell lines, derived from diffuse asbestos-related pleural malignant mesothelioma, to methotrexate alone and in combination with recombinant IFN-alpha and IFN-gamma." | 5.29 | Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. ( Hand, A; Linnainmaa, K; Mattson, K; Pelin, K, 1995) |
| "We performed a multicenter phase II trial to evaluate the impact on the activity, efficacy, symptom control and safety of using two active regimens in a sequential schedule (cisplatin/gemcitabine followed by mitoxantrone/methotrexate/mitomycin) as first-line chemotherapy for unresectable malignant pleural mesothelioma (MPM)." | 5.12 | Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). ( Benedetti, G; De Pangher Manzini, V; Del Conte, G; dell'Amore, D; Galetta, D; Giaquinta, S; Lopez, M; Marino, A; Martoni, A; Mazzanti, P; Piana, E; Pinto, C, 2006) |
| "A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment." | 3.68 | Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992) |
| "46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks." | 3.68 | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. ( Dalesio, O; Giaccone, G; Kirkpatrick, A; Mattson, K; Planteydt, HT; van Breukelen, FJ; van Zandwijk, N, 1991) |
| " The aim of this study was to assess the response of four mesothelioma cell lines, derived from diffuse asbestos-related pleural malignant mesothelioma, to methotrexate alone and in combination with recombinant IFN-alpha and IFN-gamma." | 1.29 | Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. ( Hand, A; Linnainmaa, K; Mattson, K; Pelin, K, 1995) |
| "treatment with mitoxantrone." | 1.28 | Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ( Dubbelman, R; McVie, JG; Nagel, JD; ten Bokkel Huinink, WW; Varossieau, FJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, B | 1 |
| Frei, C | 1 |
| Moura, U | 1 |
| Stahel, R | 1 |
| Felley-Bosco, E | 1 |
| Pinto, C | 2 |
| Marino, A | 2 |
| De Pangher Manzini, V | 1 |
| Benedetti, G | 1 |
| Galetta, D | 1 |
| Mazzanti, P | 1 |
| Del Conte, G | 1 |
| dell'Amore, D | 1 |
| Piana, E | 2 |
| Giaquinta, S | 1 |
| Lopez, M | 1 |
| Martoni, A | 2 |
| Hand, A | 1 |
| Pelin, K | 1 |
| Mattson, K | 2 |
| Linnainmaa, K | 1 |
| Guaraldi, M | 1 |
| Melotti, B | 1 |
| Pannuti, F | 1 |
| Verschraegen, CF | 1 |
| Vlasveld, LT | 1 |
| Taal, BG | 1 |
| Kroon, BB | 1 |
| Gallee, MP | 1 |
| Rodenhuis, S | 1 |
| Nagel, JD | 1 |
| Varossieau, FJ | 1 |
| Dubbelman, R | 1 |
| ten Bokkel Huinink, WW | 1 |
| McVie, JG | 1 |
| van Breukelen, FJ | 1 |
| Giaccone, G | 1 |
| van Zandwijk, N | 1 |
| Planteydt, HT | 1 |
| Kirkpatrick, A | 1 |
| Dalesio, O | 1 |
| Eisenhauer, EA | 1 |
| Evans, WK | 1 |
| Raghavan, D | 1 |
| Desmeules, MJ | 1 |
| Murray, NR | 1 |
| Stuart-Harris, R | 1 |
| Wilson, KS | 1 |
1 review available for mitoxantrone and Mesothelioma
| Article | Year |
|---|---|
Intracavitary therapies for mesothelioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
2 trials available for mitoxantrone and Mesothelioma
| Article | Year |
|---|---|
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, | 2006 |
Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Mesothelioma; Methotrexa | 2001 |
6 other studies available for mitoxantrone and Mesothelioma
| Article | Year |
|---|---|
Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP- | 2012 |
Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines.
Topics: Drug Interactions; Humans; Intercalating Agents; Interferon-alpha; Interferon-beta; Interferon-gamma | 1995 |
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
Topics: Adult; Biopsy; Fibrosis; Humans; Injections, Intraperitoneal; Intestinal Obstruction; Jejunal Diseas | 1992 |
Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.
Topics: Abdominal Neoplasms; Adult; Breast Neoplasms; Female; Humans; Injections, Intraperitoneal; Male; Mes | 1992 |
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Mitoxantr | 1991 |
Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Anthraquinones; Bilirubin; Creatinine; Drug Evaluation; Humans; Leukocyte Count; Mesoth | 1986 |